Callan Family Office LLC Buys Shares of 4,116 West Pharmaceutical Services, Inc. $WST

Callan Family Office LLC purchased a new stake in West Pharmaceutical Services, Inc. (NYSE:WST) during the second quarter, Holdings Channel.com reports. The firm purchased 4,116 shares of the medical instruments supplier’s stock, valued at approximately $1,478,000.

Other large investors have also recently made changes to their positions in the company. Bank of Nova Scotia grew its stake in West Pharmaceutical Services by 337.8% in the first quarter. Bank of Nova Scotia now owns 65,323 shares of the medical instruments supplier’s stock valued at $16,373,000 after purchasing an additional 50,402 shares during the last quarter. Hsbc Holdings PLC raised its holdings in West Pharmaceutical Services by 23.3% in the fourth quarter. Hsbc Holdings PLC now owns 146,872 shares of the medical instruments supplier’s stock worth $40,425,000 after purchasing an additional 27,745 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of West Pharmaceutical Services by 100.2% during the first quarter. Renaissance Technologies LLC now owns 209,660 shares of the medical instruments supplier’s stock valued at $52,549,000 after buying an additional 104,924 shares during the last quarter. Conestoga Capital Advisors LLC boosted its holdings in shares of West Pharmaceutical Services by 6.7% in the 1st quarter. Conestoga Capital Advisors LLC now owns 130,970 shares of the medical instruments supplier’s stock valued at $32,826,000 after buying an additional 8,179 shares in the last quarter. Finally, Comerica Bank raised its stake in shares of West Pharmaceutical Services by 31.8% during the 4th quarter. Comerica Bank now owns 56,693 shares of the medical instruments supplier’s stock worth $15,599,000 after acquiring an additional 13,680 shares in the last quarter. 93.90% of the stock is owned by institutional investors.

West Pharmaceutical Services Trading Down 0.0%

Shares of WST opened at $352.94 on Monday. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. The firm’s fifty day moving average is $348.61 and its two-hundred day moving average is $300.19. West Pharmaceutical Services, Inc. has a 52-week low of $223.83 and a 52-week high of $386.00. The stock has a market cap of $24.84 billion, a PE ratio of 45.19, a price-to-earnings-growth ratio of 2.47 and a beta of 1.15.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.08 by $0.29. West Pharmaceutical Services had a net margin of 16.98% and a return on equity of 20.11%. The firm had revenue of $872.30 million during the quarter, compared to analyst estimates of $839.98 million. During the same quarter in the prior year, the firm posted $1.84 earnings per share. West Pharmaceutical Services’s quarterly revenue was up 13.8% on a year-over-year basis. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Research analysts forecast that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th were issued a $0.22 dividend. This represents a $0.88 annualized dividend and a yield of 0.2%. The ex-dividend date was Wednesday, July 29th. West Pharmaceutical Services’s payout ratio is 11.27%.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on WST shares. TD Cowen reissued a “buy” rating on shares of West Pharmaceutical Services in a research report on Wednesday, July 15th. BNP Paribas Exane initiated coverage on West Pharmaceutical Services in a research report on Monday, July 13th. They set an “outperform” rating and a $447.00 price target on the stock. Wolfe Research started coverage on West Pharmaceutical Services in a report on Monday, June 1st. They set an “outperform” rating and a $375.00 price objective for the company. Morgan Stanley increased their price objective on West Pharmaceutical Services from $325.00 to $365.00 and gave the company an “equal weight” rating in a report on Thursday, July 9th. Finally, Stephens reissued an “overweight” rating and issued a $360.00 price objective on shares of West Pharmaceutical Services in a research report on Tuesday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, West Pharmaceutical Services has a consensus rating of “Moderate Buy” and an average target price of $368.08.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.